Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Interleukin Inhibitors May Give Stelara A Run For The Psoriasis Money

Executive Summary

Data showing IL-17 blockers Cosentyx and brodalumab beat J&J’s IL-12/23 inhibitor Stelara in psoriasis make a strong impression at the American Academy of Dermatology meeting, but that doesn’t necessarily mean they’ll be preferred.


Related Content

Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts